241 related articles for article (PubMed ID: 32381549)
1. Perlecan Knockdown Significantly Alters Extracellular Matrix Composition and Organization During Cartilage Development.
Ocken AR; Ku MM; Kinzer-Ursem TL; Calve S
Mol Cell Proteomics; 2020 Jul; 19(7):1220-1235. PubMed ID: 32381549
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of the pericellular matrix molecule perlecan lowers in situ cell and matrix stiffness in developing cartilage.
Xu X; Li Z; Leng Y; Neu CP; Calve S
Dev Biol; 2016 Oct; 418(2):242-7. PubMed ID: 27578148
[TBL] [Abstract][Full Text] [Related]
3. Schwartz-Jampel syndrome and perlecan deficiency.
Stum M; Davoine CS; Fontaine B; Nicole S
Acta Myol; 2005 Oct; 24(2):89-92. PubMed ID: 16550923
[TBL] [Abstract][Full Text] [Related]
4. Impact of the heparan sulfate proteoglycan perlecan on human disease and health.
Arikawa-Hirasawa E
Am J Physiol Cell Physiol; 2022 Jun; 322(6):C1117-C1122. PubMed ID: 35417267
[TBL] [Abstract][Full Text] [Related]
5. Chondroitin sulfate perlecan enhances collagen fibril formation. Implications for perlecan chondrodysplasias.
Kvist AJ; Johnson AE; Mörgelin M; Gustafsson E; Bengtsson E; Lindblom K; Aszódi A; Fässler R; Sasaki T; Timpl R; Aspberg A
J Biol Chem; 2006 Nov; 281(44):33127-39. PubMed ID: 16956876
[TBL] [Abstract][Full Text] [Related]
6. Elevated hypertrophy, growth plate maturation, glycosaminoglycan deposition, and exostosis formation in the
Shu CC; Smith SM; Little CB; Melrose J
Biochem J; 2019 Jan; 476(2):225-243. PubMed ID: 30563944
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia.
Arikawa-Hirasawa E; Le AH; Nishino I; Nonaka I; Ho NC; Francomano CA; Govindraj P; Hassell JR; Devaney JM; Spranger J; Stevenson RE; Iannaccone S; Dalakas MC; Yamada Y
Am J Hum Genet; 2002 May; 70(5):1368-75. PubMed ID: 11941538
[TBL] [Abstract][Full Text] [Related]
8. Evidence of a dosage effect and a physiological endplate acetylcholinesterase deficiency in the first mouse models mimicking Schwartz-Jampel syndrome neuromyotonia.
Stum M; Girard E; Bangratz M; Bernard V; Herbin M; Vignaud A; Ferry A; Davoine CS; Echaniz-Laguna A; René F; Marcel C; Molgó J; Fontaine B; Krejci E; Nicole S
Hum Mol Genet; 2008 Oct; 17(20):3166-79. PubMed ID: 18647752
[TBL] [Abstract][Full Text] [Related]
9. Reduced perlecan in mice results in chondrodysplasia resembling Schwartz-Jampel syndrome.
Rodgers KD; Sasaki T; Aszodi A; Jacenko O
Hum Mol Genet; 2007 Mar; 16(5):515-28. PubMed ID: 17213231
[TBL] [Abstract][Full Text] [Related]
10. Ablation of Perlecan Domain 1 Heparan Sulfate Reduces Progressive Cartilage Degradation, Synovitis, and Osteophyte Size in a Preclinical Model of Posttraumatic Osteoarthritis.
Shu CC; Jackson MT; Smith MM; Smith SM; Penm S; Lord MS; Whitelock JM; Little CB; Melrose J
Arthritis Rheumatol; 2016 Apr; 68(4):868-79. PubMed ID: 26636652
[TBL] [Abstract][Full Text] [Related]
11. Perlecan is essential for cartilage and cephalic development.
Arikawa-Hirasawa E; Watanabe H; Takami H; Hassell JR; Yamada Y
Nat Genet; 1999 Nov; 23(3):354-8. PubMed ID: 10545953
[TBL] [Abstract][Full Text] [Related]
12. A missense mutation in domain III in HSPG2 in Schwartz-Jampel syndrome compromises secretion of perlecan into the extracellular space.
Iwata S; Ito M; Nakata T; Noguchi Y; Okuno T; Ohkawara B; Masuda A; Goto T; Adachi M; Osaka H; Nonaka R; Arikawa-Hirasawa E; Ohno K
Neuromuscul Disord; 2015 Aug; 25(8):667-71. PubMed ID: 26031903
[TBL] [Abstract][Full Text] [Related]
13. Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.
Farach-Carson MC; Warren CR; Harrington DA; Carson DD
Matrix Biol; 2014 Feb; 34():64-79. PubMed ID: 24001398
[TBL] [Abstract][Full Text] [Related]
14. Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation.
Ishijima M; Suzuki N; Hozumi K; Matsunobu T; Kosaki K; Kaneko H; Hassell JR; Arikawa-Hirasawa E; Yamada Y
Matrix Biol; 2012 May; 31(4):234-45. PubMed ID: 22421594
[TBL] [Abstract][Full Text] [Related]
15. Type XI collagen-perlecan-HS interactions stabilise the pericellular matrix of annulus fibrosus cells and chondrocytes providing matrix stabilisation and homeostasis.
Smith SM; Melrose J
J Mol Histol; 2019 Jun; 50(3):285-294. PubMed ID: 30993430
[TBL] [Abstract][Full Text] [Related]
16. A biomechanical role for perlecan in the pericellular matrix of articular cartilage.
Wilusz RE; Defrate LE; Guilak F
Matrix Biol; 2012 Jul; 31(6):320-7. PubMed ID: 22659389
[TBL] [Abstract][Full Text] [Related]
17. Perlecan, the multidomain heparan sulfate proteoglycan of basement membranes, is also a prominent component of the cartilaginous primordia in the developing human fetal spine.
Melrose J; Smith S; Ghosh P; Whitelock J
J Histochem Cytochem; 2003 Oct; 51(10):1331-41. PubMed ID: 14500701
[TBL] [Abstract][Full Text] [Related]
18. Synovial perlecan is required for osteophyte formation in knee osteoarthritis.
Kaneko H; Ishijima M; Futami I; Tomikawa-Ichikawa N; Kosaki K; Sadatsuki R; Yamada Y; Kurosawa H; Kaneko K; Arikawa-Hirasawa E
Matrix Biol; 2013 Apr; 32(3-4):178-87. PubMed ID: 23339896
[TBL] [Abstract][Full Text] [Related]
19. WARP is a novel multimeric component of the chondrocyte pericellular matrix that interacts with perlecan.
Allen JM; Bateman JF; Hansen U; Wilson R; Bruckner P; Owens RT; Sasaki T; Timpl R; Fitzgerald J
J Biol Chem; 2006 Mar; 281(11):7341-9. PubMed ID: 16407285
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of HSPG2 (Perlecan) mutations in patients with Schwartz-Jampel syndrome.
Stum M; Davoine CS; Vicart S; Guillot-Noël L; Topaloglu H; Carod-Artal FJ; Kayserili H; Hentati F; Merlini L; Urtizberea JA; Hammouda el-H; Quan PC; Fontaine B; Nicole S
Hum Mutat; 2006 Nov; 27(11):1082-91. PubMed ID: 16927315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
